The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation
Latest Information Update: 18 Jul 2025
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
Most Recent Events
- 09 Jul 2025 Status changed from completed to discontinued. Reason the study was stopped: drug supply issues
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Planned primary completion date changed from 6 Jan 2022 to 6 Jan 2023.